Montefiore and Einstein Test a New Drug Combination to Conquer COVID-19
May 26, 2020—(BRONX, NY)—Montefiore Health System andAlbert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection. The new iteration of the trial, known as ACTT 2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Authors: Kim S, Jin HJ, Kim SR PMID: 32638569 [PubMed]
We report this consensus to support allergists and clinical immunologists to make optimal decisions under the urgent situation in Asia. PMID: 32638559 [PubMed]
Publication date: Available online 8 July 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Estefanía Mira, Oscar A. Yarce, Consuelo Ortega, Silvia Fernández, Natalia M. Pascual, Cristina Gómez, Miguel A. Alvarez, Ignacio J. Molina, Rafael Lama, Manuel Santamaria
BOSTON (CBS) — Dr. Mallika Marshall is answering your coronavirus-related medical questions. If you have a question for Dr. Mallika, email her or message her on Facebook or Twitter. Dr. Mallika is offering her best advice, but as always consult your personal doctor before making any decisions about your personal health. How can I use the mask without having this irritating sensation? – Isaiah, South Easton, adding he has been wearing masks since it became mandatory, but it gives him an irritating sensation Itching in the throat could be due to seasonal allergies or a reaction...
AbstractObjectivesThe aim of this study is to explore the effectiveness and safety of oral corticosteroids (prednisone) in the treatment of early stage SARS-Cov-2 pneumonia in patients who do not yet meet hospital admission criteria.Trial designRandomized clinical trial, controlled, open, parallel group, to evaluate the effectiveness of steroids in adult patients with confirmed COVID-19, with incipient pulmonary involvement, without hospital admission criteria. Patients will be stratified by the presence or not of radiological data on pneumonia.ParticipantsWe will include patients with early stage SARS-Cov-2 pneumonia who ...
(American College of Allergy, Asthma, and Immunology) Due to COVID-19, the 2020 ACAAI Annual Scientific Meeting will be held remotely.
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has established a new clinical trials network that aims to enroll thousands of volunteers in large-scale clinical trials testing a variety of investigational vaccines and monoclonal antibodies intended to protect people from COVID-19.
(University of South Carolina) UofSC researchers from its Big Data Health Science Center initiative have received $1.25 million in grant funding from the NIH National Institute of Allergy and Infectious Diseases (NIAID) to develop a data-driven system to track COVID-19 in South Carolina.
(Fred Hutchinson Cancer Research Center) Fred Hutchinson Cancer Research Center has been named the coordinating center for vaccine clinical trials of the COVID-19 Prevention Network (COVPN), funded by the National Institute of Allergy and Infectious Diseases.
DiscussionAlthough both investigational drugs are often administered off label to patients with severe COVID-19, at present, there is no data from RCTs on their safety and efficacy. In vitro and observational trial suggests their potential to limit viral replication and the damage to lungs as the most common reason for ICU admission. Therefore, patients most likely to benefit from the treatment are those with severe but early disease. This trial is designed and powered to investigate whether the treatment in this cohort of patients leads to improved clinical patient-centred outcomes, such as mechanical ventilation-free sur...